Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Nimenrix immunogenicity in at-risk children and adolescents versus healthy controls
2011-002410-36Phase 3Completed
- Sponsor
- GSK
- Start
- May 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity in terms of vaccine response. Started May 2012; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2011-002410-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002410-36.